NeOnc Technologies Holdings is trading at $3.41, up 5.90%, after Roth/MKM initiated coverage on September 24, 2026, with a Buy rating and a $20 price target. - The analyst cited the development outlook for NEO100 and NEO212, along with positive NEO100 Phase 2a data. - The analyst also pointed to potential pivotal trials by year-end 2026. - The move appears company-specific despite broader biotech weakness during regular trading.